SHEPPARD & ENOCH PRATT HOSPITAL
1. Target Overview & Investment Thesis
SHEPPARD & ENOCH PRATT HOSPITAL is a 335-bed safety-net/medicaid heavy in BALTIMORE, MD with $170.0M in net patient revenue and a -62.0% operating margin. The hospital serves a payer mix of 11.1% Medicare, 38.8% Medicaid, and 50.1% commercial.
Thesis: Undervalued. Our ML models identify $12.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -62.0% to -54.7% (+736bps).
| Net Revenue HCRIS | $170.0M |
| Current EBITDA COMPUTED | $-105.5M |
| Operating Margin COMPUTED | -62.0% |
| Occupancy HCRIS | 90.7% |
| Revenue / Bed COMPUTED | $508K |
| Net-to-Gross HCRIS | 82.9% |
| Distress Probability ML | 54.3% |
2. Market Context & Competitive Position
MD has 59 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of -62.0% places it below the state median. Among 29 size-comparable peers (168-670 beds), the median margin is -8.9%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (168-670), prioritizing same-state peers. 29 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| SHEPPARD & ENOCH PRATT HOSPITA (Target) | MD | 335 | $170.0M | -62.0% |
| SINAI HOSPITAL OF BALTIMORE I | MD | 459 | $820.9M | -20.6% |
| JOHNS HOPKINS BAYVIEW MED. CTR | MD | 424 | $654.4M | -17.1% |
| ANNE ARUNDEL MEDICAL CENTER IN | MD | 379 | $616.6M | -3.3% |
| MERCY MEDICAL CENTER | MD | 173 | $561.3M | -3.3% |
| MEDSTAR FRANKLIN SQUARE MEDICA | MD | 354 | $537.6M | -5.7% |
| HOLY CROSS HOSPITAL | MD | 399 | $516.0M | -16.7% |
| ST. AGNES HOSPITAL | MD | 183 | $506.7M | -12.2% |
| TIDALHEALTH PENINSULA REGIONAL | MD | 230 | $493.4M | 0.8% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $12.5M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $3.6M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $3.4M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $3.4M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $2.1M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $109K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-105.5M |
| + RCM Uplift | +$12.5M |
| Pro Forma EBITDA | $-92.9M |
| Current Margin | -62.0% |
| Pro Forma Margin | -54.7% |
| WC Released (1x) | $6.5M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-162.2M | $-570.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-162.2M | $-680.2M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-146.0M | $-691.6M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-146.0M | $-797.6M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-178.5M | $-580.4M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-178.5M | $-696.3M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (38.8%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 54.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 29 hospitals with 168-670 beds
- Same-state prioritization (n=30)
- Comp margins: P25=-14.4% / P50=-8.9% / P75=-4.3%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.